Covalently linked-ADC as a new and innovative technology for cancer therapy
The enzymatic covalently conjugated drugs, CovIsoLink allows the coupling of 2 drug molecules on a specific site of 1 monoclonal antibody. We aim to validate the proof of concept of our new & patented technology compared to the existing T-DM1 ADC for breast cancer developed by chemical conjugation. The new CovHer2-ADC will be studied in vitro & in vivo using T-DM1 ADC as a reference. The results expected are homogenous ADC preparations rather than mixtures resulting in greater efficacy & safety.
1 386 220.00€
Cytology, Cancerology, Oncology
Drug delivery and other equipment (including kidney dialysis machines)